Does congestive heart failure cause high blood pressure

2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–1562. doi: 10.1001/jama.1996.03530440037034. [PubMed] [CrossRef] [Google Scholar]

3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N. doi: 10.1016/S0002-9149(98)00583-9. [PubMed] [CrossRef] [Google Scholar]

4. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987;317:787–792. doi: 10.1056/NEJM198709243171302. [PubMed] [CrossRef] [Google Scholar]

5. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–1297. doi: 10.1056/NEJMoa003417. [PubMed] [CrossRef] [Google Scholar]

6. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:1273–1284. doi: 10.2337/dci17-0026. [PubMed] [CrossRef] [Google Scholar]

7. Otsuka T, Takada H, Nishiyama Y, Kodani E, Saiki Y, Kato K, et al. Dyslipidemia and the Risk of Developing Hypertension in a Working-Age Male Population. J Am Heart Assoc. 2016;5:e003053. doi: 10.1161/JAHA.115.003053. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008;26:1477–1486. doi: 10.1097/HJH.0b013e3282fe1d3d. [PubMed] [CrossRef] [Google Scholar]

9. Yamasaki N, Kitaoka H, Matsumura Y, Furuno T, Nishinaga M, Doi Y. Heart failure in the elderly. Intern Med. 2003;42:383–388. doi: 10.2169/internalmedicine.42.383. [PubMed] [CrossRef] [Google Scholar]

10. Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med Clin North Am. 2004;88:115–130. doi: 10.1016/S0025-7125(03)00168-8. [PubMed] [CrossRef] [Google Scholar]

11. Lazzeroni D, Rimoldi O, Camici PG. From Left Ventricular Hypertrophy to Dysfunction and Failure. Circ J. 2016;80:555–564. doi: 10.1253/circj.CJ-16-0062. [PubMed] [CrossRef] [Google Scholar]

12. Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failure: Contemporary Update. JACC Heart Fail. 2017;5:543–551. doi: 10.1016/j.jchf.2017.04.012. [PubMed] [CrossRef] [Google Scholar]

13. Mȕller AL. Differences in Concentric Cardiac Hypertrophy and Eccentric Hypertrophy. Cardiac Adaptations Advances in Biochemistry in Health and Disease. 2013. [Google Scholar]

14. Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension. 2004;43:1182–1188. doi: 10.1161/01.HYP.0000128738.94190.9f. [PubMed] [CrossRef] [Google Scholar]

15. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72:310–313. doi: 10.1016/0002-9149(93)90678-6. [PubMed] [CrossRef] [Google Scholar]

16. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: A population study of hypertensive subjects. Eur Heart J. 2010;31:588–594. doi: 10.1093/eurheartj/ehp490. [PubMed] [CrossRef] [Google Scholar]

17. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550–1558. doi: 10.1016/0735-1097(92)90617-V. [PubMed] [CrossRef] [Google Scholar]

18. Devereux RB, James GD, Pickering TG. What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens. 1993;6:211S–215S. [PubMed] [Google Scholar]

19. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103:102–107. doi: 10.1161/01.CIR.103.1.102. [PubMed] [CrossRef] [Google Scholar]

20. Zabalgoitia M, Berning J, Koren MJ, Stoylen A, Nieminen MS, Dahlof B, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study) Am J Cardiol. 2001;88:646–650. doi: 10.1016/S0002-9149(01)01807-0. [PubMed] [CrossRef] [Google Scholar]

21. Gottdiener JS, Reda DJ, Materson BJ, Massie BM, Notargiacomo A, Hamburger RJ, et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol. 1994;24:1492–1498. doi: 10.1016/0735-1097(94)90145-7. [PubMed] [CrossRef] [Google Scholar]

22. du Cailar G, Pasquie JL, Ribstein J, Mimran A. Left ventricular adaptation to hypertension and plasma renin activity. J Hum Hypertens. 2000;14:181–188. doi: 10.1038/sj.jhh.1000974. [PubMed] [CrossRef] [Google Scholar]

23. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:89–96. doi: 10.1016/j.jacc.2006.01.077. [PubMed] [CrossRef] [Google Scholar]

24. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–1126. doi: 10.1016/j.jacc.2008.11.051. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–2096. doi: 10.1161/CIRCULATIONAHA.105.573865. [PubMed] [CrossRef] [Google Scholar]

26. Iriarte M, Murga N, Sagastagoitia D, Morillas M, Boveda J, Molinero E, et al. Classification of hypertensive cardiomyopathy. Eur Heart J. 1993;14(Suppl J):95–101. [PubMed] [Google Scholar]

27. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88:1444–1455. doi: 10.1161/01.CIR.88.4.1444. [PubMed] [CrossRef] [Google Scholar]

28. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014;311:2387–2396. doi: 10.1001/jama.2014.5616. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Simone G, Izzo R, Chinali M, Marco MD, Casalnuovo G, Rozza F, et al. Does Information on Systolic and Diastolic Function Improve Prediction of a Cardiovascular Event by Left Ventricular Hypertrophy in Arterial Hypertension? Hypertension. 2010;56:99–104. doi: 10.1161/HYPERTENSIONAHA.110.150128. [PubMed] [CrossRef] [Google Scholar]

30. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879–884. doi: 10.1016/0735-1097(94)00473-4. [PubMed] [CrossRef] [Google Scholar]

31. Tsioufis C, Kokkinos P, Macmanus C, Thomopoulos C, Faselis C, Doumas M, et al. Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens. 2010;28:2299–2308. doi: 10.1097/HJH.0b013e32833d95fe. [PubMed] [CrossRef] [Google Scholar]

32. Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G, et al. Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension. J Hypertens. 2017;35:1727–1741. doi: 10.1097/HJH.0000000000001396. [PubMed] [CrossRef] [Google Scholar]

33. Collins S, Martindale J. Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction. Curr Hypertens Rep. 2018;20:9. doi: 10.1007/s11906-018-0809-7. [PubMed] [CrossRef] [Google Scholar]

34. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714–720. doi: 10.1161/01.CIR.0000048123.22359.A0. [PubMed] [CrossRef] [Google Scholar]

35. Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17:1172–1181. doi: 10.1002/ejhf.344. [PubMed] [CrossRef] [Google Scholar]

36. Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF) Korean Circ J. 2017;47:341–353. doi: 10.4070/kcj.2016.0419. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the korean heart failure registry. Korean Circ J. 2011;41:363–371. doi: 10.4070/kcj.2011.41.7.363. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018;15:e1002541. doi: 10.1371/journal.pmed.1002541. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159:949–955. doi: 10.1016/j.ahj.2010.03.019. [PubMed] [CrossRef] [Google Scholar]

40. Adams KF, Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J. 2005;149:209–216. doi: 10.1016/j.ahj.2004.08.005. [PubMed] [CrossRef] [Google Scholar]

41. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, Committee ASA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J. 2007;153:1021–1028. doi: 10.1016/j.ahj.2007.03.012. [PubMed] [CrossRef] [Google Scholar]

42. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613–625. doi: 10.1002/ejhf.566. [PubMed] [CrossRef] [Google Scholar]

43. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46. doi: 10.1016/S0002-9343(03)00158-X. [PubMed] [CrossRef] [Google Scholar]

44. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol. 2008;101:1151–1156. doi: 10.1016/j.amjcard.2007.12.014. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725–2736. doi: 10.1093/eurheartj/ehl193. [PubMed] [CrossRef] [Google Scholar]

46. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–2226. doi: 10.1001/jama.296.18.2217. [PubMed] [CrossRef] [Google Scholar]

47. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Committee ASA, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76–84. doi: 10.1016/j.jacc.2005.09.022. [PubMed] [CrossRef] [Google Scholar]

48. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–1852. doi: 10.1161/CIR.0b013e31829e8807. [PubMed] [CrossRef] [Google Scholar]

49. Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 2002;39:1182–1188. doi: 10.1016/S0735-1097(02)01737-0. [PubMed] [CrossRef] [Google Scholar]

50. Yip GW, Fung JW, Tan YT, Sanderson JE. Hypertension and heart failure: a dysfunction of systole, diastole or both? J Hum Hypertens. 2009;23:295–306. doi: 10.1038/jhh.2008.141. [PubMed] [CrossRef] [Google Scholar]

51. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective SC. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11911-8. [PubMed] [CrossRef] [Google Scholar]

52. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) Circulation. 2011;124:1727–1736. doi: 10.1161/CIRCULATIONAHA.110.008870. [PubMed] [CrossRef] [Google Scholar]

53. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press. 2016;25:1–3. doi: 10.3109/08037051.2016.1096564. [PubMed] [CrossRef] [Google Scholar]

54. Group SR, Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103–2116. doi: 10.1056/NEJMoa1511939. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

55. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615–1621. doi: 10.1161/hc3901.096700. [PubMed] [CrossRef] [Google Scholar]

56. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350–2356. doi: 10.1001/jama.292.19.2350. [PubMed] [CrossRef] [Google Scholar]

57. Kim H, Jun DW, Cho YK, Nam CW, Han SW, Hur SH, et al. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction. Echocardiography. 2008;25:961–967. doi: 10.1111/j.1540-8175.2008.00717.x. [PubMed] [CrossRef] [Google Scholar]

58. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens. 2012;30:1681–1689. doi: 10.1097/HJH.0b013e3283569a9c. [PubMed] [CrossRef] [Google Scholar]

59. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials. J Hypertens. 2016;34:373–384. doi: 10.1097/HJH.0000000000000848. [PubMed] [CrossRef] [Google Scholar]

60. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898. doi: 10.1056/NEJMoa0801369. [PubMed] [CrossRef] [Google Scholar]

61. Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20. doi: 10.1186/s40885-019-0124-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) J Am Coll Cardiol. 2008;52:347–356. doi: 10.1016/j.jacc.2008.04.028. [PubMed] [CrossRef] [Google Scholar]

63. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009;95:56–62. doi: 10.1136/hrt.2007.134973. [PubMed] [CrossRef] [Google Scholar]

64. Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004;43:1423–1429. doi: 10.1016/j.jacc.2003.11.037. [PubMed] [CrossRef] [Google Scholar]

65. Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol. 2008;52:2000–2007. doi: 10.1016/j.jacc.2008.09.011. [PubMed] [CrossRef] [Google Scholar]

66. Bohm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38:1132–1143. doi: 10.1093/eurheartj/ehw570. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

67. Lip GY, Skjoth F, Overvad K, Rasmussen LH, Larsen TB. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. Clin Res Cardiol. 2015;104:1088–1096. doi: 10.1007/s00392-015-0878-4. [PubMed] [CrossRef] [Google Scholar]

68. Tsika EP, Poulimenos LE, Boudoulas KD, Manolis AJ. The J-curve in arterial hypertension: fact or fallacy? Cardiology. 2014;129:126–135. doi: 10.1159/000362381. [PubMed] [CrossRef] [Google Scholar]

69. Lip S, Tan LE, Jeemon P, McCallum L, Dominiczak AF, Padmanabhan S. Diastolic Blood Pressure J-Curve Phenomenon in a Tertiary-Care Hypertension Clinic. Hypertension. 2019;74:767–775. doi: 10.1161/HYPERTENSIONAHA.119.12787. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

70. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897–2908. doi: 10.1093/eurheartj/ehq328. [PubMed] [CrossRef] [Google Scholar]

71. Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. JACC Heart Fail. 2017;5:810–819. doi: 10.1016/j.jchf.2017.08.015. [PubMed] [CrossRef] [Google Scholar]

What is the blood pressure of someone with congestive heart failure?

What are the signs of worsening congestive heart failure?

How does heart failure cause high blood pressure?

What is the first stage of congestive heart failure?